All In Biotech

Drug Trial Radar · NCT06496178

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 621 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

621

Actual

Start

Jun 25, 2024

Primary completion

Feb 2028

Study completion Mar 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • PetosemtamabDrug

    MCLA-158

  • Investigator's ChoiceDrug

    Cetuximab

  • Investigator's ChoiceDrug

    Methotrexate

  • Investigator's ChoiceDrug

    Docetaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 3 years

Locations

188 sites in 24 countries. Site status is shown where the registry gives one.

  • Site 160

    Mobile, Alabama

  • Site 102

    Prescott, Arizona

  • Site 125

    Scottsdale, Arizona

  • Site 82

    Duarte, California

  • Site 25

    La Jolla, California

  • Site 173

    Orange, California

  • Site 28

    Palo Alto, California

  • Site 127

    Sacramento, California

  • Site 46

    San Francisco, California

  • Site 130

    Lone Tree, Colorado

  • Site 104

    Washington D.C., District of Columbia

  • Site 12

    Fort Myers, Florida

  • Site 123

    Jacksonville, Florida

  • Site 9

    Orlando, Florida

  • Site 138

    Tampa, Florida

  • Site 187

    Atlanta, Georgia

  • Site 152

    Chicago, Illinois

  • Site 213

    Chicago, Illinois

  • Site 68

    Chicago, Illinois

  • Site 31

    Indianapolis, Indiana

  • Site 8

    Louisville, Kentucky

  • Site 40

    Baton Rouge, Louisiana

  • Site 100

    New Orleans, Louisiana

  • Site 153

    Columbia, Maryland

  • Site 77

    Boston, Massachusetts

  • Site 103

    Ann Arbor, Michigan

  • Site 5

    Detroit, Michigan

  • Site 49

    Maple Grove, Minnesota

  • Site 124

    Rochester, Minnesota

  • Site 18

    St Louis, Missouri

  • Site 15

    Albuquerque, New Mexico

  • Site 24

    New York, New York

  • Site 214

    The Bronx, New York

  • Site 98

    Chapel Hill, North Carolina

  • Site 122

    Durham, North Carolina

  • Site 23

    Cincinnati, Ohio

  • Site 218

    Cleveland, Ohio

  • Site 87

    Cleveland, Ohio

  • Site 32

    Columbus, Ohio

  • Site 26

    Portland, Oregon

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.